Article info
PDFCommentary
Nocebo effects: a price worth paying for full transparency?
- Correspondence to Dr Brian McMillan, Centre for Primary Care and Health Services Research, The University of Manchester, Manchester, UK; brian.mcmillan{at}manchester.ac.uk
Citation
Nocebo effects: a price worth paying for full transparency?
Publication history
- Received November 14, 2022
- Accepted November 17, 2022
- First published December 1, 2022.
Online issue publication
December 19, 2022
Article Versions
- Previous version (1 December 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Sharing online clinical notes with patients: implications for nocebo effects and health equity
- Unethical informed consent caused by overlooking poorly measured nocebo effects
- Response to commentaries on sharing online clinical notes with patients: implications for nocebo effects and health equity
- ‘Scan-negative’ cauda equina syndrome: what to do when there is no neurosurgical cause
- Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection
- The nocebo effect: patient expectations and medication side effects
- Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
- Prescribing placebos ethically: the appeal of negatively informed consent
- Cauda equina syndrome
- Understanding cauda equina syndrome: protocol for a UK multicentre prospective observational cohort study